GSK's albiglutide GLP-1 agonist hits endpoint in a second PhIII trial
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline said it has received top-line results from seven of the eight “Harmony” Phase III studies investigating use of its once-weekly experimental GLP-1 agonist albiglutide in type 2 diabetes. It is pleased with the results it has reviewed and plans to continue to push ahead with its overall programme.